Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

SNDX

Syndax Pharmaceuticals Inc

Pharmaceutical Preparations · SIC 2834CIK 1395937Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$172.0M
Net Income FY2025
$(285.0M)
EPS (Basic, as reported)
$-3.29
Net Margin FY2025
-165.6%
ROE FY2025
-441.6%
Total Equity
$65.0M
Shares Out
89M
Business description

Syndax Pharmaceuticals Inc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 1 → 172 +77.2% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue122221400024172
Research & development(32)(48)(60)(43)(50)(88)(118)(163)(242)(259)
Selling, general & administrative—————(25)(33)(67)(121)(180)
General & administrative(13)(16)(17)(16)(23)(25)(33)———
Total operating expenses(45)(64)(77)(59)(73)(113)(152)(230)(363)(445)
Operating income(44)(62)(76)(58)(71)26(152)(230)(340)(273)
Interest expense————(2)(2)(3)000
Interest & investment income——22106212623
Other income (expense), net(1)121(2)(1)22121(12)
Income tax expense000000———0
Net income(44)(61)(74)(56)(73)25(149)(209)(319)(285)
EPS — basic———($1.84)($1.87)$0.48($2.46)($2.98)($3.72)($3.29)
EPS — diluted———($1.84)($1.87)$0.46($2.46)($2.98)($3.72)($3.29)
Shares outstanding — basic (M)———30415261708687
Shares outstanding — diluted (M)———30415461708687

Showing the latest 10 of 12 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.